Osimertinib is the only approved third-generation EGFR-TKI for T790M-positive patients progressed on first- or second generation EGFR-TKIs [2,3]; moreover, it has recently been approved as first-line therapy for advanced EGFR-mutated NSCLC [4], considering the benefit in progression-free survival (PFS) and overall survival (OS) as compared with gefitinib or erlotinib evidenced in the FLAURA trial [5,6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.